Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMADEUS: Nivolumab +/- Ipilimumab in Advanced Cancer
NCT03651271Phase 2Completed
- Sponsor
- Parker Institute for Cancer Immunotherapy
- Start
- Oct 2018
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in metastatic cancer and prostate cancer (PCa) (5 arms), sponsored by Parker Institute for Cancer Immunotherapy. Primary endpoints: Clinical Benefit Rate up to 43 months and Percentage of Participants Whose Tumors Convert From CD8 Low to CD8 High up to 8 months. Started Oct 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
metastatic cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT03651271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651271.